search
Back to results

Neurostatus-SMARTCARE in Comparison to Standard Neurostatus-EDSS® (SMARTCARE)

Primary Purpose

Multiple Sclerosis (MS)

Status
Recruiting
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Neurostatus-SMARTCARE
Standard Neurostatus-EDSS
Sponsored by
University Hospital, Basel, Switzerland
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Multiple Sclerosis (MS) focused on measuring Expanded Disability Status Scale (EDSS), Neurostatus, Neurostatus-eEDSS, Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB)

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 18 years old at the time of signing the informed consent
  • Clinically definite MS, confirmed through the medical chart
  • At least one documented EDSS assessment within two (2) years prior to inclusion
  • The participant must be capable of giving signed informed consent

Exclusion Criteria:

  • Insufficient knowledge of the German language, i.e. inability to understand the patient information or to follow the instructions and questions during the EDSS assessment

Sites / Locations

  • Neurologic Clinic and Policlinic, University Hospital Basel
  • Luzerner KantonsspitalRecruiting
  • Reha Rheinfelden

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Group A

Group B

Arm Description

First neurologist, second nurse

First nurse, second neurologist

Outcomes

Primary Outcome Measures

Inter-rater reliability, i.e. the concordance rate between Neurostatus-SMARTCARE and Neurostatus-EDSS® at EDSS step level
The pairwise concordance among all EDSS-steps between a neurologist's and a nurse's assessment of the the same participant at one visit will be tested and an overall concordance rate of all EDSS-steps. The true concordance level needs to be at least 89% to have a reasonable chance of demonstrating that the observed rate is significantly higher than 80%. If this can be shown, it can be concluded that Neurostatus-SMARTCARE is equivalent to the standardized Neurostatus-EDSS in clinical routine or clinical trials. This would allow HCPs to assess the Neurostatus-EDSS with the same quality as neurologists.

Secondary Outcome Measures

Inter-rater reliability at subscore level between Neurostatus-SMARTCARE and standard Neurostatus-EDSS®
The pairwise concordance among all subscores between a neurologist's and a nurse's assessment of the the same participant at one visit will be tested and an overall concordance rate of all subscores.
Inter-rater reliability at Functional System Score (FSS) levels between Neurostatus-SMARTCARE and standard Neurostatus-EDSS®
The pairwise concordance among all FSS between a neurologist's and a nurse's assessment of the the same participant at one visit will be tested and an overall concordance rate of all FSS.
Number of assessments rated correctly by neurologists in comparison to HCPs
When discrepancies occur between neurologists and nurses at EDSS step level, it will be calculated how often the neurologists had assessed the correct result and how often the nurses.
Number and type of the same error occurring more than once at the individual rater level
It will be tested if raters make the same error more than once, i.e. if they make typical errors that could be corrected through re-training. Therefore the number of "more-than-once-errors" will be collected and the type of error, e.g. errors through a false examination technique or a calculation error in determining the FSS/ EDSS step.
Inter-rater reliability in capturing the number of changes in the Expanded Disability Status Scale (EDSS) through worsening and progression or improvement occurring between the first and second measurement.
I twill be tested if neurologists and nurses detect EDSS changes after 6 months equally, i.e. if they assign the same changed EDSS step. Note: Changes in the EDSS are defined in steps of 0.5 points. Increasing numbers of the EDSS step mean worsening, decreasing numbers mean improvement. An increase of 1.0 point ocover 3 months is usually considered MS progression.

Full Information

First Posted
September 7, 2022
Last Updated
June 19, 2023
Sponsor
University Hospital, Basel, Switzerland
Collaborators
Novartis Pharma AG, Basel, Switzerland
search

1. Study Identification

Unique Protocol Identification Number
NCT05575843
Brief Title
Neurostatus-SMARTCARE in Comparison to Standard Neurostatus-EDSS®
Acronym
SMARTCARE
Official Title
Neurostatus-SMARTCARE in Comparison to Standard Neurostatus- EDSS® - a Swiss Multicenter Randomized Cross-over Study
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 9, 2022 (Actual)
Primary Completion Date
March 2024 (Anticipated)
Study Completion Date
March 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Basel, Switzerland
Collaborators
Novartis Pharma AG, Basel, Switzerland

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The Expanded Disability Status Scale (EDSS) is the gold-standard in assessing disability in Multiple Sclerosis (MS). Its current digital form, the Neurostatus-eEDSS®, often serves as primary endpoint in MS clinical trials. The pandemic revealed the need for telemedical alternatives to the in-clinic assessment. Therefore, Neurostatus-SMARTCARE was developed: A trained and certified non-neurologist Health Care Professional (HCP) examines the patient while the examination is being video-recorded. The stored video allows a neurologist to re-assess the examination at a later point of time. The future application could be in-home visits through HCPs, in decentralized clinical trials as well as in routine care. In this study, the concordance rate of Neurostatus examinations between neurologists and HCPs is investigated. With a concordance rate significantly higher than 80%, Neurostatus-SMARTCARE by HCPs can be considered equal to the standard Neurostatus-EDSS by neurologists.
Detailed Description
In MS, a specific form of the neurological assessment is the gold-standard to evaluate patients' clinical activity and the evolvement of disability over time: the EDSS. The scale was introduced in 1983 by Kurtzke and has been developed further to the "Neurostatus" by Kappos and co-workers for better reproducibility. In 2011 a digital format of the Neurostatus-EDSS was implemented, the Neurostatus-eEDSS®. It often serves as primary endpoint in MS clinical trials. Neurostatus-eEDSS® organizes the neurological examination into 8 chapters, which are: visual functional system (FS), brainstem FS, pyramidal FS, cerebellar FS, sensory FS, bowel and bladder FS, cerebral FS and ambulation score. The eight chapters are in turn composed of individual elements (subscores) that investigate neurological functions. Thus, the Neurostatus-eEDSS® results in a total of 121 subcores which are synthetized into 7 FS scores and an ambulation score. The result of the 7 FS scores plus the ambulation score is the EDSS step. The best EDSS step score - 0 (zero) - identifies a normal neurologic examination, and the worst score - 10 (ten) - stands for death due to MS. In-between are intervals of 0.5 steps. The pandemic revealed the need for telemedical alternatives when as well clinical visits as study visits couldn't be continued routinely. Therefore, the Neurostatus-SMARTCARE was developed: A trained and certified non-neurologist Health Care Professional performs the EDSS examination with the patient while the examination is being video-recorded. The stored video allows a neurologist at a later time-point to review and re-assess the examination and to establish his/ her diagnostic and therapeutic evaluations on it. If the complementary Neurostatus-form "SMARTCARE (smartly modernized assessment - recorded, telemedical, care professional-assisted, remotely evaluated)" was equal to the standard Neurostatus-EDSS, it could be applied at patients' homes in decentralized clinical trials or telemedical clinical consultations. In this study the Neurostatus-SMARTCARE, performed by trained HCPs is compared to the standard Neurostatus-EDSS, performed by neurologists. At two routine clinical visits a neurologist and a nurse perform the EDSS one after the other with a break for the patient as needed. To account for potential sequence effects, the order of assessment is randomly assigned to "first neurologist, then nurse" (group A) and "first nurse, then neurologist" (group B). At the next clinical consultation (visit 2), the reverse order is applied. All assessments are video-recorded. Each pair of assessment is compared with regard to concordance as to the 3 levels of the scale: EDSS step, Functional System Scores (FSS) and subscores. Comparison is automated in a digital tool. In case of discrepancies, an EDSS expert assesses the videos to determine, which is the correct examination result. The neurologists and nurses are blinded to each others' assessment results and to the participants' previous EDSS step. The experts are blinded to the raters' identity until the moment of watching a video.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Multiple Sclerosis (MS)
Keywords
Expanded Disability Status Scale (EDSS), Neurostatus, Neurostatus-eEDSS, Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB)

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
Multicentre randomized cross-over study: Randomization 1:1 to group A and group B. Group A undergoes first the Neurostatus-EDSS® and afterwards the Neurostatus-SMARTCARE. Group B starts with the Neurostatus-SMARTCARE and finishes with the Neurostatus-EDSS®. At the next visit the reverse order is applied, by the same neurologist and HCP.
Masking
Outcomes Assessor
Masking Description
The HCPs and neurologists performing the examinations are blinded to each others' assessment scores and to the results of previous clinical EDSS examinations. The evaluating experts are blinded to the raters' identity until watching an examination video.
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Group A
Arm Type
Other
Arm Description
First neurologist, second nurse
Arm Title
Group B
Arm Type
Other
Arm Description
First nurse, second neurologist
Intervention Type
Other
Intervention Name(s)
Neurostatus-SMARTCARE
Intervention Description
The Neurostatus-EDSS is assessed by HCPs while the examination is video-recorded. HCPs underwent extended training. For details of the examination refer to the second section of the detailed description.
Intervention Type
Other
Intervention Name(s)
Standard Neurostatus-EDSS
Intervention Description
The Neurostatus-EDSS is assessed by neurologists while the examination is video-recorded. Neurologists underwent standard training.
Primary Outcome Measure Information:
Title
Inter-rater reliability, i.e. the concordance rate between Neurostatus-SMARTCARE and Neurostatus-EDSS® at EDSS step level
Description
The pairwise concordance among all EDSS-steps between a neurologist's and a nurse's assessment of the the same participant at one visit will be tested and an overall concordance rate of all EDSS-steps. The true concordance level needs to be at least 89% to have a reasonable chance of demonstrating that the observed rate is significantly higher than 80%. If this can be shown, it can be concluded that Neurostatus-SMARTCARE is equivalent to the standardized Neurostatus-EDSS in clinical routine or clinical trials. This would allow HCPs to assess the Neurostatus-EDSS with the same quality as neurologists.
Time Frame
1.5 - 2 hours per study visit for each participant
Secondary Outcome Measure Information:
Title
Inter-rater reliability at subscore level between Neurostatus-SMARTCARE and standard Neurostatus-EDSS®
Description
The pairwise concordance among all subscores between a neurologist's and a nurse's assessment of the the same participant at one visit will be tested and an overall concordance rate of all subscores.
Time Frame
1.5 - 2 hours per study visit for each participant
Title
Inter-rater reliability at Functional System Score (FSS) levels between Neurostatus-SMARTCARE and standard Neurostatus-EDSS®
Description
The pairwise concordance among all FSS between a neurologist's and a nurse's assessment of the the same participant at one visit will be tested and an overall concordance rate of all FSS.
Time Frame
1.5 - 2 hours per study visit for each participant
Title
Number of assessments rated correctly by neurologists in comparison to HCPs
Description
When discrepancies occur between neurologists and nurses at EDSS step level, it will be calculated how often the neurologists had assessed the correct result and how often the nurses.
Time Frame
Through study completion, an average of 1.5 years
Title
Number and type of the same error occurring more than once at the individual rater level
Description
It will be tested if raters make the same error more than once, i.e. if they make typical errors that could be corrected through re-training. Therefore the number of "more-than-once-errors" will be collected and the type of error, e.g. errors through a false examination technique or a calculation error in determining the FSS/ EDSS step.
Time Frame
Through study completion, an average of 1.5 years
Title
Inter-rater reliability in capturing the number of changes in the Expanded Disability Status Scale (EDSS) through worsening and progression or improvement occurring between the first and second measurement.
Description
I twill be tested if neurologists and nurses detect EDSS changes after 6 months equally, i.e. if they assign the same changed EDSS step. Note: Changes in the EDSS are defined in steps of 0.5 points. Increasing numbers of the EDSS step mean worsening, decreasing numbers mean improvement. An increase of 1.0 point ocover 3 months is usually considered MS progression.
Time Frame
Through study completion, an average of 1.5 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18 years old at the time of signing the informed consent Clinically definite MS, confirmed through the medical chart At least one documented EDSS assessment within two (2) years prior to inclusion The participant must be capable of giving signed informed consent Exclusion Criteria: Insufficient knowledge of the German language, i.e. inability to understand the patient information or to follow the instructions and questions during the EDSS assessment
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Marcus D'Souza, PD Dr. med.
Phone
+41 61 556 58 54
Email
marcus.dsouza@usb.ch
First Name & Middle Initial & Last Name or Official Title & Degree
Andrea Zimmer, MScN
Phone
+41 61 556 53 35
Email
andrea.zimmer@usb.ch
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ludwig Kappos, Prof. Dr. med. Dr. h. c. mult.
Organizational Affiliation
Foundation Clinical Neuroimmunology and Neuroscience Basel (RC2NB)
Official's Role
Study Director
Facility Information:
Facility Name
Neurologic Clinic and Policlinic, University Hospital Basel
City
Basel
ZIP/Postal Code
4031
Country
Switzerland
Individual Site Status
Active, not recruiting
Facility Name
Luzerner Kantonsspital
City
Luzern 16
ZIP/Postal Code
6000
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christian Kamm, Prof. Dr. med.
Phone
+41 41 205 29 69
Email
christian.kamm@luks.ch
First Name & Middle Initial & Last Name & Degree
Christian Kamm, Prof. Dr. med
Facility Name
Reha Rheinfelden
City
Rheinfelden
ZIP/Postal Code
4310
Country
Switzerland
Individual Site Status
Withdrawn

12. IPD Sharing Statement

Learn more about this trial

Neurostatus-SMARTCARE in Comparison to Standard Neurostatus-EDSS®

We'll reach out to this number within 24 hrs